Infecciones por el virus de Epstein-Barr y citomegalovirus

  1. Tinoco Racero, I.
  2. Caro Gómez, N.
  3. Rodríguez Leal, M. C.
  4. López Tinoco, Elena
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2014

Título del ejemplar: Enfermedades infecciosas (II): infecciones víricas

Serie: 11

Número: 50

Páginas: 2954-2964

Tipo: Artículo

DOI: 10.1016/S0304-5412(14)70722-X DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La infección por el virus de Epstein-Barr es la causa más frecuente de la mononucleosis infecciosa. Describimos su diagnóstico y los distintos patrones serológicos que se pueden presentar, así como sus principales complicaciones, relación con el desarrollo de neoplasias, síndromes linfoproliferativos y enfermedades autoinmunes. No existe un tratamiento efectivo. El citomegalovirus es la segunda causa de síndrome mononucleósido, la primera de infección congénita en nuestro medio y presenta gran morbimortalidad en los pacientes inmunodeprimidos, fundamentalmente trasplantados de órganos sólidos, médula ósea e infección por el virus de la inmunodeficiencia humana. Su tratamiento se basa en los antivíricos, sobre todo ganciclovir y valganciclovir. Describimos su manejo, efectos adversos, principales alternativas, nuevos fármacos y profilaxis.

Referencias bibliográficas

  • Adler SP. Immunization to prevent congenital cytomegalovirus infection. Br Med . 2013;107:57-68.
  • Aguado JM, Navarro D, San Juan R, Castón JJ. Cytomegalovirus infection in solid organ transplantation. Enferm Infecc Microbiol Clin. 2012;30Suppl2:57-62.
  • Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a minireview. Cancer Lett. 2014;342(1):1-8.
  • Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489-96.
  • Benoist G, Leruez-Ville M, Magny JF, Jacquemard F, Salomon LJ, Ville Y. Management of pregnancies with confirmed cytomegalovirus fetal infec-tion. Fetal Diagn Ther. 2013;33:203-14.
  • Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117:53-62.
  • Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131:e1424-7.
  • Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276-82.
  • Crumpacker CS II, Zhang JL. Cytomegalovirus. Mandell, Douglas and Bennett ́s Principle and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2010. p. 1971-87.
  • De la Torre-Cisneros J, Fariñas MC, Castón JJ, Aguado JM, Cantisán S, Carratalá J. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin. 2011;29 735-58.
  • Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep. 2012;7:208-15.
  • Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70:1279-87.
  • Enders G, Daiminger A, Bäder U, Exler S, Schimpf Y, Enders M. The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy. J Clin Virol. 2013;56:102-7.
  • Epstein Barr virus, including infectious mononucleosis. Harrison ́s Principles of Internal Medicine. 18th ed. USA: McGraw-Hill; 2012.
  • Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus related disease. J Mol Diagn. 2008;10:279-92.
  • Härter G, Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother. 2012;13:6237.
  • Hodson E, Barclay P, Craig J, Jones C, Kable K, Strippoli G. Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2007;(2):CD005129.
  • Hussain RS, Hussain NA. Ataxia and encephalitis in a young adult with EBV mononucleosis: a case report. Case Rep Neurol Med. 2013. Dis-ponible en: dx.doi.org/10.1155/2013/516325.
  • Jain M, Duggal S, Chugh TD. Cytomegalovirus infection in non immunosuppressed critically ill patients. J Infect Dev Ctries. 2011;5:571-9.
  • Johannsen EC, Kaye KM. Epstein-Barr (infectious mononucleosis, Epstein-Barr virus associated malignant diseases, and other diseases). Mandell, Douglas and Bennett ́s Principle and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2010. p. 1989-2010.
  • Klemola E, Von Essen R, Henle G, Henle W. Infectious mononucleosis like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis. 1970;121:608-14.
  • Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis: association and causation. Viruses. 2012;4:3701-30.
  • Lunn M, Hughes R. The relationship between cytomegalovirus infection and Guillain–Barré syndrome. Clin Infect Dis. 2011;52: 845-7.
  • Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362:1993-2000.
  • Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associ-ated with haemophagocytic syndrome. Rev Med Virol 2010; 20: 93-105.
  • Macsween KF, Higgins CD, McAulay KA, Williams H, Harrison N, Swerdlow AJ. Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis. 2010;50:699-706.
  • Moormann AM, Snider CJ, Chelimo K. The company malaria keeps: how coinfection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis. 2011;24:435-41.
  • Morris MC, Edmunds WJ. The changing epidemiology of infectious mononucleosis? J Infect. 2002;45:107-9.
  • Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13: R68.
  • Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151-7.
  • Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a sys-tematic review. Virol J. 2008;5: 47.
  • Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost. 2011;106:858-67.
  • Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:466-74.
  • Santos Luna F, Carratalà J. Tratamiento de la enfermedad por citomegalovirus. Enferm Infecc Microbiol Clin. 2011;29Suppl6:65-9.
  • Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112-6.
  • Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803-21.
  • Thorley-Lawson DA, Gross A. Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328-37.
  • Tomtishen JP 3rd. Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virol J. 2012;9:22. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol. 2012;19:14-20.
  • Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54.
Fuente de los datos: Dialnet